#1 Clinical Trials Search in Europe

PROMESTRIENE

PROMESTRIENE is a topical estrogen medication that has been studied in various clinical trials for the treatment of vaginal dryness and atrophy. These conditions commonly affect women after menopause or during certain health conditions like Sjögren’s disease or following breast cancer treatment. Clinical trials have compared PROMESTRIENE with other treatment options such as CO2 laser therapy, radiofrequency treatments, and different estrogen formulations to evaluate its effectiveness and safety. This article explores how PROMESTRIENE has been used in clinical trials and what the research reveals about its potential benefits for women experiencing vaginal discomfort.

Table of Contents

What is Promestriene?

Promestriene (also known as Promestrieno or Colpotrofine) is a synthetic estrogen compound used primarily for topical application in the vaginal area. It’s specifically designed to treat various genital conditions related to estrogen deficiency without causing significant systemic effects[1]. Unlike other estrogen treatments that can be absorbed into the bloodstream and affect the entire body, promestriene works mainly at the application site, making it a safer option for many patients.

Medical Conditions Treated with Promestriene

Promestriene is primarily used to treat the following conditions:

  • Vaginal Atrophy – A condition where the vaginal tissues become thinner, drier, and less elastic due to decreased estrogen levels, commonly occurring during menopause[2]
  • Vulvovaginal Atrophy (VVA) – Similar to vaginal atrophy but also affects the external genital tissues[2]
  • Vaginitis Sicca – Dry inflammation of the vagina, often seen in patients with Sjögren’s Disease[1]
  • Dyspareunia – Painful sexual intercourse, often resulting from vaginal dryness[2]
  • Urogenital Syndrome (UGS) – A collection of symptoms affecting the genital and urinary systems due to estrogen deficiency[1]
  • Vaginal dryness in breast cancer patients – Where systemic hormone therapy may be contraindicated[3]

Mechanism of Action

Promestriene works through several mechanisms to improve vaginal health:

  • Increases the thickness of vaginal epithelium (the lining of the vagina)[2]
  • Improves vaginal lubrication and reduces dryness[2]
  • Helps normalize vaginal pH to a more acidic level (typically between 3.8 and 4.5), which helps prevent infections[2]
  • Promotes collagen formation and improves tissue elasticity[2]
  • Increases vascularization (blood flow) to vaginal tissues[2]
  • Positively affects the vaginal microbiota, helping maintain a healthy bacterial balance[2]

Unlike systemic estrogens, promestriene has minimal absorption into the bloodstream, which means it doesn’t significantly impact other body systems or organs like the endometrium (lining of the uterus)[2].

Clinical Applications

Treatment of Vaginal Dryness in Sjögren’s Disease

Sjögren’s Disease is a chronic, immune-mediated, systemic inflammatory disease characterized by dryness of various body parts, including the vagina. Clinical trials have shown that promestriene can effectively treat vaginal dryness (vaginitis sicca) in patients with Sjögren’s Disease[1]. In one study, patients applied a 10 mg promestriene vaginal capsule nightly for fifteen consecutive days, followed by one application every three days for up to six months[1].

Management of Postmenopausal Vaginal Atrophy

Promestriene has been extensively studied for treating vaginal atrophy in postmenopausal women. Clinical trials have demonstrated improvements in the Vaginal Health Index (VHI), which measures elasticity, fluid volume, pH, epithelial integrity, and moisture[2]. Studies have also shown reduced symptoms of dryness, itching, burning, and pain after treatment[7].

Treatment for Breast Cancer Patients

Women treated for breast cancer often experience symptoms of vulvovaginal atrophy but may not be candidates for systemic hormone therapy. Promestriene offers a local treatment option with minimal systemic absorption, making it potentially suitable for these patients[3]. In clinical trials, breast cancer survivors used promestriene daily for two weeks and then twice weekly for three months, with positive results for vaginal health[3].

Preoperative Treatment in Hypospadias

Interestingly, promestriene has also been studied as a preoperative treatment for severe hypospadias (a congenital condition where the opening of the urethra is not at the usual location on the penis). The theory is that local estrogen treatment might improve skin healing and reduce post-operative complications[4]. In this application, promestriene cream is applied to the penile skin once daily for two months prior to surgery[4].

Comparison with Other Treatments

Several clinical trials have compared promestriene with other treatments for vaginal atrophy:

Promestriene vs. Fractional CO2 Laser

Studies have compared promestriene with vaginal fractional CO2 laser treatment for vaginal atrophy. Both treatments showed improvements in vaginal health, but through different mechanisms. The laser treatment works by stimulating collagen production and vascularization, while promestriene provides direct hormonal effects[1] [2].

Promestriene vs. Microablative Radiofrequency

Clinical trials have also compared promestriene with microablative radiofrequency treatment. Both approaches demonstrated efficacy in improving vaginal symptoms, with differences in the onset and duration of effects[3].

Promestriene vs. Other Vaginal Estrogens

Comparisons between promestriene and other estrogen products (such as 10 micrograms of estradiol vaginal tablets) have been conducted to evaluate differences in acceptability, efficacy, and safety. These studies help determine which patients might benefit most from each specific treatment[6].

Dosage and Administration

Based on clinical trial protocols, promestriene is typically administered as follows:

  • For vaginal atrophy: 10 mg vaginal capsule or cream applied daily for the first 15 days (or two weeks), followed by applications every 2-3 days for maintenance[2] [6]
  • For Sjögren’s Disease: 10 mg vaginal capsule applied nightly for fifteen consecutive days, then one application every three days for up to six months[1]
  • For breast cancer patients: Daily application for 2 weeks, then twice weekly for 3 months[3]
  • For hypospadias (preoperative): 1g of cream applied once daily for 2 months[4]

The medication is typically applied using an applicator that comes with the product, following the instructions in the package insert[6].

Safety Profile

Promestriene has several safety advantages compared to systemic estrogen therapies:

  • Minimal systemic absorption – This means very little of the medication enters the bloodstream[2]
  • No significant effect on endometrial thickness – Studies monitoring endometrial thickness by ultrasound have shown minimal changes[5] [6]
  • No significant impact on hormone levels – Studies measuring estradiol, testosterone, LH, and FSH showed minimal changes after promestriene use[4]
  • Well-tolerated – Clinical trials report few adverse effects[3]

However, as with any medication, some patients may experience mild local irritation or allergic reactions. Clinical trials have specifically monitored for adverse events and have generally found promestriene to be well-tolerated[6].

Use in Special Populations

Breast Cancer Patients

Promestriene may be an option for breast cancer survivors who experience vaginal atrophy but cannot use systemic hormone therapy. Clinical trials have specifically included breast cancer patients to evaluate the safety and efficacy of promestriene in this population[3].

Patients with Sjögren’s Disease

Patients with Sjögren’s Disease often experience severe vaginal dryness that affects their quality of life. Clinical studies have shown that promestriene can effectively treat these symptoms and improve quality of life measures[1].

Pre-menopausal vs. Post-menopausal Women

While most studies focus on postmenopausal women, some trials have included both pre- and post-menopausal patients, particularly those with specific conditions like Sjögren’s Disease. The efficacy appears consistent across these groups, though dosing may vary[1].

In conclusion, promestriene is a topical estrogen medication that effectively treats various conditions related to vaginal atrophy and dryness. Its primary advantage is providing local benefits with minimal systemic effects, making it suitable for patients who cannot or prefer not to use systemic hormone therapy. Clinical trials continue to evaluate its efficacy compared to newer treatment modalities like laser therapy and radiofrequency, helping to define its optimal place in treatment algorithms.

Clinical Trial Focus Treatment Protocol Comparison Treatments Key Outcome Measures
Vaginal dryness in Sjögren’s Disease 10 mg vaginal capsule applied nightly for 15 consecutive days, then every 3 days for 6 months Fractional CO2 laser (3 monthly applications) Vaginal Health Index, Visual Analogue Scale of dryness, quality of life questionnaires
Postmenopausal vaginal atrophy Daily application for 2 weeks, then twice weekly Fractional CO2 laser, Microablative fractional radiofrequency Vaginal pH, tissue biopsy analysis, Female Sexual Function Index
Vulvovaginal atrophy in breast cancer survivors Daily application for 2 weeks, then twice weekly for 3 months CO2 laser, Microablative radiofrequency Vaginal flora, pH, histologic evaluation, quality of life, sexual function
Hypospadias treatment (pediatric) 1g per day for 2 months prior to surgery Placebo Post-operative complications, wound healing
Pelvic organ prolapse with vaginal atrophy 1g per day Conjugated estrogen, Estriol, Vaginal moisturizer Endometrial thickness, histopathological effects, climacteric complaints
Comparison with estradiol vaginal tablets Daily application for 2 weeks, then twice weekly with 3-day intervals 10 micrograms estradiol vaginal tablets Relief of symptoms, pH changes, vaginal maturation index, endometrial thickness

FAQ

  • What is PROMESTRIENE and how does it work? PROMESTRIENE is a topical estrogen medication that is applied vaginally to treat symptoms of vaginal dryness and atrophy. It works by providing localized estrogen to vaginal tissues, which helps restore moisture, elasticity, and normal pH to the vaginal area. Unlike systemic hormone therapies, PROMESTRIENE is designed to work primarily on the vaginal tissues with minimal absorption into the bloodstream.
  • What conditions is PROMESTRIENE used to treat in clinical trials? In the clinical trials examined, PROMESTRIENE has been studied for treating vaginal dryness and atrophy in several conditions including: postmenopausal vulvovaginal atrophy, vaginal dryness in primary Sjögren's disease, vaginal atrophy in women who have been treated for breast cancer, and as a preoperative treatment for children with severe hypospadias (a congenital condition of the urethra in males).
  • How is PROMESTRIENE typically applied according to clinical trials? The application protocol in most trials involves an initial intensive phase followed by a maintenance phase. Typically, PROMESTRIENE is applied daily for the first two weeks (15 days in some trials), then reduced to twice weekly or every three days for maintenance therapy. The medication usually comes as a vaginal cream or soft capsules that are inserted using an applicator provided with the product.
  • How does PROMESTRIENE compare to other treatments for vaginal atrophy? Clinical trials have compared PROMESTRIENE to other treatments like fractional CO2 laser therapy, microablative fractional radiofrequency, and other estrogen formulations such as estradiol vaginal tablets. These studies aim to determine which treatments provide the best outcomes for improving vaginal health, reducing symptoms, and enhancing quality of life while minimizing side effects or risks.
  • What outcome measures are used to evaluate PROMESTRIENE's effectiveness in clinical trials? Researchers use several measures to evaluate PROMESTRIENE's effectiveness, including: Vaginal Health Index (VHI), which assesses elasticity, fluid volume, pH, epithelial integrity, and moisture; Visual Analogue Scale (VAS) for symptom severity; histological analysis of vaginal tissue samples; changes in vaginal pH; maturation index of vaginal cells; quality of life questionnaires; and sexual function assessments like the Female Sexual Function Index (FSFI).

Ongoing Clinical Trials on PROMESTRIENE

  • Study on Improving Sexual Health and Quality of Life in Cervical Cancer Patients Using Estriol, Estradiol Hemihydrate, and Promestriene

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Vulvovaginal Atrophy: A condition where the vaginal tissues become thinner, drier, and less elastic due to decreased estrogen levels, typically occurring after menopause or in certain health conditions.
  • Sjögren's Disease: A chronic, immune-mediated, systemic inflammatory disease that primarily affects the salivary and lacrimal glands, causing dryness in various body tissues including the mouth, eyes, and vagina.
  • Promestriene: A topical estrogen medication used to treat vaginal dryness and atrophy, designed to work locally with minimal systemic absorption.
  • Vaginitis Sicca: A condition characterized by vaginal dryness, which can cause irritation, itching, burning, and pain during intercourse.
  • Fractional CO2 Laser: A medical device that uses laser energy to create tiny wounds in vaginal tissue, stimulating new tissue growth and collagen production to improve vaginal health.
  • Microablative Fractional Radiofrequency: A treatment that uses radiofrequency energy to heat vaginal tissues, stimulating collagen production and improving tissue health and elasticity.
  • Vaginal Health Index (VHI): A clinical assessment tool that measures five parameters of vaginal health: elasticity, fluid volume, pH, epithelial integrity, and moisture, with scores ranging from 5 (worst) to 25 (best).
  • Maturation Index (MI): A measurement of the proportions of different cell types in vaginal tissue that indicates the level of estrogen effect, used to evaluate vaginal atrophy.
  • Dyspareunia: Pain during sexual intercourse, often a symptom of vaginal dryness or atrophy.
  • Female Sexual Function Index (FSFI): A questionnaire used to assess women's sexual function across six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain.
  • Visual Analogue Scale (VAS): A measurement tool where patients rate their symptoms (like pain or dryness) on a scale, typically from 0 to 10, with higher numbers indicating more severe symptoms.
  • pH: A measure of how acidic or alkaline a substance is. Healthy vaginal pH is typically acidic (3.8 to 4.5), but becomes more alkaline in vaginal atrophy.
  • Hypospadias: A congenital condition in males where the opening of the urethra is not located at the tip of the penis but on the underside.
  • Urogenital Syndrome (UGS): A collection of symptoms affecting the urinary tract and genital area, typically occurring after menopause due to decreased estrogen levels.
  • Histomorphometric analysis: The measurement and study of the form and structure of tissues under a microscope, used to evaluate changes in vaginal tissue after treatment.

References

  1. https://clinicaltrials.gov/study/NCT07153276
  2. https://clinicaltrials.gov/study/NCT04717245
  3. https://clinicaltrials.gov/study/NCT04081805
  4. https://clinicaltrials.gov/study/NCT01370798
  5. https://clinicaltrials.gov/study/NCT03032848
  6. https://clinicaltrials.gov/study/NCT04232813
  7. https://clinicaltrials.gov/study/NCT04657536